Al Hammadi Holding currently operates two hospitals in Saudi Arabia, with Al Olaya Hospital and Al Hammadi Hospital Al Narjis expected to launch in 2026 and 2028. In H1 2025, the group reported $705.6 million in total assets and $160 million in revenues. In 2024, the group’s medical services, which include inpatient and outpatient operations at both Al Nuzha and Al Suwaidi hospitals, reported revenue of $253.6 million, accounted for 82% of the company’s consolidated top-line. Meanwhile, Al Hammadi’s pharmaceutical sales contributed 18% of consolidated revenue, recording $54 million. Al Hammadi is also a chairman of Al-Baha Investment and Development.